Preclinical Data for CPL423 Kinase Inhibitor in Cancer Models

2026 data from Agata Mikołajczyk details the preclinical evaluation of CPL423, a small-molecule inhibitor targeting TAM kinases and FLT3. The study reports sub-nanomolar IC50 values, such as 0.47 nM for MERTK and 0.94 nM for FLT3, and demonstrates up to 98% tumor growth inhibition in AML xenograft models. It includes results from in vitro kinase assays, antiproliferative tests on cell lines, and in vivo efficacy studies in xenograft models.

Use Cases

• Analyze IC50 values for TAM kinases and FLT3 to compare CPL423's potency against other kinase inhibitors.
• Model the relationship between tumor growth inhibition percentages and compound dosage in AML xenograft and A375 melanoma models.
• Correlate in vitro antiproliferative effects in MOLM-13 and MV4-11 cell lines with in vivo xenograft efficacy data.

Strengths

• Reports precise, sub-nanomolar biochemical potency metrics, including a 0.47 nM IC50 for MERTK inhibition.
• Includes multiple experimental validation layers: in vitro kinase assays, cell line studies, and in vivo xenograft models.
• Data is recent, with a last update in March 2026, and is shared under a permissive CC BY 4.0 license.

Limitations

• The dataset is contained within a single 673.2 KB DOCX file, limiting machine-readability and automated analysis.
• No structured tabular data (rows/columns) or sample data is provided, requiring manual extraction from the document text.
• Scope is limited to preclinical findings for a single compound, CPL423, without comparative data for other inhibitors.

Provenance

Source

Agata Mikołajczyk via figshare.

Collection Method

Experimental data from in vitro kinase assays, cell culture studies, and in vivo xenograft models.

Time Range

Study period not specified; data reflects preclinical experiments.

Freshness

Last updated on 2026-03-25.